LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Inicio・Lista de Acciones・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Cerrado

13.94 8.48

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.79

Máximo

13.94

Métricas clave
By Trading Economics
Ingresos	-6.4M -20M
Ventas	-807K 71M
BPA	-0.13
Margen de beneficios	-28.24
Empleados	624
EBITDA	-7.9M -14M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+55.63% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-282M 2B
Apertura anterior	5.46
Cierre anterior	13.94

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

8.81 / 10.18 Soporte y Resistencia

Adaptive Biotechnologies Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2026, 23:31 UTC

Acciones populares

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 may 2026, 22:52 UTC

Principales Movimientos del Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 may 2026, 23:44 UTC

Ganancias

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 may 2026, 23:35 UTC

Charlas de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 may 2026, 23:30 UTC

Charlas de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 23:17 UTC

Charlas de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 may 2026, 23:15 UTC

Charlas de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 may 2026, 23:14 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 may 2026, 23:02 UTC

Charlas de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

20 may 2026, 22:57 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 may 2026, 22:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2026, 22:27 UTC

Charlas de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 may 2026, 22:14 UTC

Charlas de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 may 2026, 22:10 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 may 2026, 22:00 UTC

Ganancias

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 may 2026, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 may 2026, 21:27 UTC

Ganancias

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 may 2026, 21:20 UTC

Ganancias

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 may 2026, 21:19 UTC

Ganancias

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 may 2026, 21:18 UTC

Ganancias

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 may 2026, 21:17 UTC

Ganancias

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 may 2026, 21:17 UTC

Ganancias

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 may 2026, 21:16 UTC

Ganancias

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparación entre iguales

Cambio de precio

Adaptive Biotechnologies Corp previsión

Precio Objetivo

By TipRanks

55.63% repunte

Estimación a 12 Meses

Media 20.17 USD 55.63%

Máximo 22 USD

Mínimo 18 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Adaptive Biotechnologies Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Adaptive Biotechnologies Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.81 / 10.18Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.